Nanobiotix Reports Wider Net Loss Amid Revenue Decline
Nanobiotix reported its Q2FY27 results, which showed a net loss of €34.3 million for the first half of 2026, a significant expansion from the €5.4 million loss recorded in the same period of 2025.
The widened deficit stems primarily from a steep decline in revenue and other income, which fell to €5.6 million from €26.6 million year-on-year.
R&D expenses decreased slightly to €12.7 million from €14.5 million, while the cash position strengthened significantly during the period, aided by a successful capital raise.
Nanobiotix's lead candidate JNJ-1900 (NBTXR3) showed 79% locoregional control in Phase 1 NSCLC study, with early results from the Johnson & Johnson-led CONVERGE Study indicating an overall response rate of 85.7% and a complete response rate of 57.1% in seven patients.